{"id":23147,"date":"2020-09-28T10:11:26","date_gmt":"2020-09-28T08:11:26","guid":{"rendered":"https:\/\/kymos.com\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/"},"modified":"2026-03-04T21:11:12","modified_gmt":"2026-03-04T20:11:12","slug":"kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group","status":"publish","type":"post","link":"https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/","title":{"rendered":"Kymos y Prolytic se fusionan para convertirse en Kymos Group"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:calc( 1170px + 20px );margin-left: calc(-20px \/ 2 );margin-right: calc(-20px \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-blend:overlay;--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:10px;--awb-margin-bottom-large:0px;--awb-spacing-left-large:10px;--awb-width-medium:100%;--awb-spacing-right-medium:10px;--awb-spacing-left-medium:10px;--awb-width-small:100%;--awb-spacing-right-small:10px;--awb-spacing-left-small:10px;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><h3 class=\"\" style=\"--fontsize: 17; line-height: 1.67; --minfontsize: 17;\" data-fontsize=\"17\" data-lineheight=\"28.39px\"><span style=\"font-size: 14pt;\"><strong>Con la incorporaci\u00f3n de la CRO alemana al grupo europeo, Kymos reforzar\u00e1 su actividad en el mercado de biol\u00f3gicos y terapias avanzadas y ampliar\u00e1 su cartera de servicios, ofreciendo a la vez tres sedes locales en Europa<\/strong><\/span><\/h3>\n<div class=\"blog-content\">\n<div class=\"field field-name-body field-type-text-with-summary field-label-hidden\">\n<div class=\"field-items\">\n<div class=\"field-item even\">\n<p><span style=\"font-size: 14pt;\"><strong>Barcelona, Espa\u00f1a, y Fr\u00e1ncfort, Alemania, 28 de septiembre de 2020<\/strong> \u2013 <a href=\"https:\/\/kymos.com\/es\/kymos\/\" data-wpel-link=\"internal\">Kymos S.L<\/a>. y <a href=\"https:\/\/kymos.com\/es\/prolytic\/\" data-wpel-link=\"internal\">Prolytic GmbH<\/a> anuncian hoy la finalizaci\u00f3n de una exitosa fusi\u00f3n estrat\u00e9gica para integrar Prolytic en Kymos Group, con el fin de ofrecer servicios de valor a\u00f1adido a compa\u00f1\u00edas biofarmac\u00e9uticas de todo el mundo, con una soluci\u00f3n verdaderamente paneuropea en un entorno empresarial en r\u00e1pida evoluci\u00f3n. <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">La combinaci\u00f3n de conocimientos permitir\u00e1 a las empresas ampliar su cartera con una selecci\u00f3n \u00fanica de servicios para mol\u00e9culas peque\u00f1as y grandes innovadoras, gen\u00e9ricos, biosimilares, anticuerpos, biomarcadores, ADA (anticuerpos anti-f\u00e1rmaco), ADC (conjugados anticuerpo-f\u00e1rmaco), hormonas, enzimas y \u00e1cidos nucleicos. Tambi\u00e9n intensificar\u00e1n su actividad en el mercado de terapias avanzadas. El inter\u00e9s por las prote\u00ednas recombinantes y por las terapias celulares y g\u00e9nicas avanzadas est\u00e1 en auge actualmente en Europa y en todo el mundo. Prolytic ha adquirido experiencia en tecnolog\u00edas de ARNm, que se utilizan en algunas de las vacunas contra la Covid-19 m\u00e1s avanzadas que se est\u00e1n desarrollando en Europa.   <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Las dos empresas, junto con Pharmaprogress, una filial de Kymos Group en Italia, comparten un compromiso con la calidad y una dedicaci\u00f3n a la innovaci\u00f3n. Aunque los clientes tendr\u00e1n acceso a una gama ampliada de servicios certificados GMP\/GLP y conformes con GCP, seguir\u00e1n obteniendo un servicio a medida, personalizado y genuinamente flexible, no visto en ninguna otra CRO de su tama\u00f1o. Kymos y Prolytic cuentan con una comprensi\u00f3n multidisciplinar de todo el proceso de desarrollo y fabricaci\u00f3n farmac\u00e9utica, desde las fases de desarrollo y cl\u00ednicas hasta la aprobaci\u00f3n final y los estudios poscomercializaci\u00f3n, aportando seguridad log\u00edstica y fiabilidad. La fusi\u00f3n supondr\u00e1 una mejora en la capacidad de la empresa para reaccionar a\u00fan m\u00e1s r\u00e1pido ante las necesidades espec\u00edficas de sus clientes globales.   <\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><em>\u00abEl mercado actual quiere proveedores de servicio integral y soluciones de ventanilla \u00fanica. Con esta fusi\u00f3n podremos pensar globalmente y actuar localmente, ofreciendo a nuestros clientes un servicio fiable, de confianza y muy mejorado\u00bb,<\/em> afirm\u00f3 la Dra. Dorothee Krone, directora general de Prolytic. <em>\u00abLas empresas peque\u00f1as y medianas se sienten c\u00f3modas trabajando con nosotros. Kymos puede ayudarnos a cubrir todo el ciclo de las ciencias de la vida y ahora podemos ofrecer una gama de servicios mucho m\u00e1s diversa que la que jam\u00e1s hab\u00edamos podido ofrecer en el pasado\u00bb.<\/em><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><em>\u00abEl conocimiento que Prolytic tiene sobre el ADN y el ARN es un elemento cient\u00edfico clave del mercado de servicios de terapias avanzadas en el que Kymos est\u00e1 entrando\u00bb,<\/em> afirm\u00f3 el Sr. Joan Puig de Dou, CEO de Kymos. <em>\u00abLa fusi\u00f3n nos brinda la oportunidad de ampliar nuestra oferta de servicios, reforzar el mercado emergente de terapias y crear una empresa multinacional y multidisciplinar. Esperamos con gran inter\u00e9s esta nueva etapa en la historia de la empresa\u00bb.<\/em><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Con esta fusi\u00f3n, Kymos cuenta ahora con tres sedes en Europa: Barcelona (Espa\u00f1a), Ancona (Italia) y Fr\u00e1ncfort (Alemania). La sede italiana es el resultado de la fusi\u00f3n de 2016 con Pharmaprogress SRL. En virtud del acuerdo, los nombres de las empresas permanecer\u00e1n sin cambios. En la sede alemana de Prolytic, la direcci\u00f3n actual seguir\u00e1 en su puesto, mientras que aumentar\u00e1 el n\u00famero de empleados. Se pondr\u00e1 en marcha un plan de inversi\u00f3n para adquirir equipamiento de \u00faltima generaci\u00f3n.    <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Tras reforzar su ya destacada presencia en la UE, el grupo europeo aspira a expandirse en la regi\u00f3n Asia-Pac\u00edfico, abriendo al mismo tiempo nuevas \u00e1reas terap\u00e9uticas prometedoras.<\/span><\/p>\n<p><strong style=\"font-size: 14pt; color: var(--body_typography-color); font-family: var(--body_typography-font-family); font-style: var(--body_typography-font-style,normal); letter-spacing: var(--body_typography-letter-spacing);\">Acerca de Prolytic <\/strong><\/p>\n<p><span style=\"font-size: 14pt;\">Prolytic GmbH es experta en bioan\u00e1lisis y farmacocin\u00e9tica, con capacidades especializadas de investigaci\u00f3n por contrato en bioan\u00e1lisis y evaluaciones farmacocin\u00e9ticas bajo GLP y GCP.<\/span><br \/><span style=\"font-size: 14pt;\">Ofrece una gama de servicios sofisticados en el desarrollo y la validaci\u00f3n de m\u00e9todos anal\u00edticos para el an\u00e1lisis y la cuantificaci\u00f3n de mol\u00e9culas peque\u00f1as, prote\u00ednas, anticuerpos y ant\u00edgenos, ADA (anticuerpos anti-f\u00e1rmaco), biomarcadores y biosimilares, as\u00ed como enzimas intactas, adem\u00e1s del an\u00e1lisis de muestras para estudios precl\u00ednicos y cl\u00ednicos. Prolytic puede realizar an\u00e1lisis cualitativos o cuantitativos de f\u00e1rmacos y metabolitos en sangre, plasma, orina, tejido u otras matrices biol\u00f3gicas. Asimismo, tambi\u00e9n puede llevar a cabo evaluaciones farmacocin\u00e9ticas compartimentales y no compartimentales. Como empresa innovadora, Prolytic es l\u00edder en proyectos de cooperaci\u00f3n en investigaci\u00f3n financiados por el Estado en el \u00e1mbito del desarrollo de biomarcadores de ARN y las terapias avanzadas.   <\/span><br \/><span style=\"font-size: 14pt;\">Creada en 2002 y con sede en Fr\u00e1ncfort, Prolytic cuenta con 17 empleados y 1.000 metros cuadrados de instrumentaci\u00f3n de \u00faltima generaci\u00f3n.<\/span><\/p>\n<p><span style=\"font-size: 18.6667px;\"><a href=\"https:\/\/kymos.com\/es\/prolytic\/\" data-wpel-link=\"internal\">kymos.com\/prolytic<\/a><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>Acerca de Kymos<\/strong><\/span><br \/><span style=\"font-size: 14pt;\">Kymos S.L. es l\u00edder mundial y uno de los diez principales proveedores globales de servicios de ensayo de biosimilares, con a\u00f1os de experiencia en biol\u00f3gicos, mol\u00e9culas peque\u00f1as y servicios integrales tanto en CMC como en bioan\u00e1lisis. Como organizaci\u00f3n europea de laboratorio por contrato certificada GLP\/GMP, conforme con GCP e inspeccionada por la EMA y la FDA, especializada en bioan\u00e1lisis y CMC, Kymos ofrece estudios completos de bioequivalencia, incluidos biowaivers para DP t\u00f3picos, bioan\u00e1lisis de mol\u00e9culas peque\u00f1as y grandes, ADA y ensayos de liberaci\u00f3n de lotes para ensayos precl\u00ednicos y cl\u00ednicos en Europa. Kymos tambi\u00e9n ofrece servicios de CMC para el desarrollo de m\u00e9todos, la caracterizaci\u00f3n y la comparabilidad de biosimilares, adem\u00e1s de a\u00f1os de experiencia con clientes biofarmac\u00e9uticos de todo el mundo.  <\/span><br \/><span style=\"font-size: 14pt;\">Creada en 2001 y con sede central en Barcelona, Kymos cuenta con 110 empleados y 3.000 m2 de instalaciones, con instrumentaci\u00f3n de primera l\u00ednea. La filial italiana cuenta con 20 empleados adicionales y alrededor de 1.000 m2 de instalaciones. Se espera que la facturaci\u00f3n conjunta de las tres empresas supere los 13 M\u20ac ($15,1 M) en 2020.  <\/span><br \/><span style=\"font-size: 14pt;\"><a href=\"https:\/\/kymos.com\/es\/\" data-wpel-link=\"internal\">Kymos<\/a><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":6,"featured_media":21660,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[184,182],"tags":[],"class_list":["post-23147","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-grupo-kymos","category-noticias"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kymos y Prolytic se fusionan para convertirse en Kymos Group | Kymos<\/title>\n<meta name=\"description\" content=\"Kymos S.L. y Prolytic GmbH anuncian una exitosa fusi\u00f3n estrat\u00e9gica para integrar Prolytic en Kymos Group.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kymos y Prolytic se fusionan para convertirse en Kymos Group | Kymos\" \/>\n<meta property=\"og:description\" content=\"Kymos S.L. y Prolytic GmbH anuncian una exitosa fusi\u00f3n estrat\u00e9gica para integrar Prolytic en Kymos Group.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/\" \/>\n<meta property=\"og:site_name\" content=\"Kymos\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-28T08:11:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-04T20:11:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"494\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Joan Puig de Dou\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:site\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Joan Puig de Dou\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\\\/\"},\"author\":{\"name\":\"Joan Puig de Dou\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"headline\":\"Kymos y Prolytic se fusionan para convertirse en Kymos Group\",\"datePublished\":\"2020-09-28T08:11:26+00:00\",\"dateModified\":\"2026-03-04T20:11:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\\\/\"},\"wordCount\":1184,\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\",\"articleSection\":[\"Kymos Group\",\"Noticias\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\\\/\",\"url\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\\\/\",\"name\":\"Kymos y Prolytic se fusionan para convertirse en Kymos Group | Kymos\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\",\"datePublished\":\"2020-09-28T08:11:26+00:00\",\"dateModified\":\"2026-03-04T20:11:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"description\":\"Kymos S.L. y Prolytic GmbH anuncian una exitosa fusi\u00f3n estrat\u00e9gica para integrar Prolytic en Kymos Group.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\",\"contentUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\",\"width\":900,\"height\":494,\"caption\":\"Kymos and Prolytic\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kymos.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kymos y Prolytic se fusionan para convertirse en Kymos Group\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/kymos.com\\\/es\\\/\",\"name\":\"Kymos Group\",\"description\":\"Kymos Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kymos.com\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\",\"name\":\"Joan Puig de Dou\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"caption\":\"Joan Puig de Dou\"},\"description\":\"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.\",\"url\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/author\\\/joan-puig-de-dou\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kymos y Prolytic se fusionan para convertirse en Kymos Group | Kymos","description":"Kymos S.L. y Prolytic GmbH anuncian una exitosa fusi\u00f3n estrat\u00e9gica para integrar Prolytic en Kymos Group.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/","og_locale":"es_ES","og_type":"article","og_title":"Kymos y Prolytic se fusionan para convertirse en Kymos Group | Kymos","og_description":"Kymos S.L. y Prolytic GmbH anuncian una exitosa fusi\u00f3n estrat\u00e9gica para integrar Prolytic en Kymos Group.","og_url":"https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/","og_site_name":"Kymos","article_published_time":"2020-09-28T08:11:26+00:00","article_modified_time":"2026-03-04T20:11:12+00:00","og_image":[{"width":900,"height":494,"url":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","type":"image\/png"}],"author":"Joan Puig de Dou","twitter_card":"summary_large_image","twitter_creator":"@KymosGroup","twitter_site":"@KymosGroup","twitter_misc":{"Escrito por":"Joan Puig de Dou","Tiempo de lectura":"6 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/#article","isPartOf":{"@id":"https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/"},"author":{"name":"Joan Puig de Dou","@id":"https:\/\/kymos.com\/es\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"headline":"Kymos y Prolytic se fusionan para convertirse en Kymos Group","datePublished":"2020-09-28T08:11:26+00:00","dateModified":"2026-03-04T20:11:12+00:00","mainEntityOfPage":{"@id":"https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/"},"wordCount":1184,"image":{"@id":"https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","articleSection":["Kymos Group","Noticias"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/","url":"https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/","name":"Kymos y Prolytic se fusionan para convertirse en Kymos Group | Kymos","isPartOf":{"@id":"https:\/\/kymos.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/#primaryimage"},"image":{"@id":"https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","datePublished":"2020-09-28T08:11:26+00:00","dateModified":"2026-03-04T20:11:12+00:00","author":{"@id":"https:\/\/kymos.com\/es\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"description":"Kymos S.L. y Prolytic GmbH anuncian una exitosa fusi\u00f3n estrat\u00e9gica para integrar Prolytic en Kymos Group.","breadcrumb":{"@id":"https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/#primaryimage","url":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","contentUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","width":900,"height":494,"caption":"Kymos and Prolytic"},{"@type":"BreadcrumbList","@id":"https:\/\/kymos.com\/es\/news\/kymos-y-prolytic-se-fusionan-para-convertirse-en-kymos-group\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kymos.com\/es\/"},{"@type":"ListItem","position":2,"name":"Kymos y Prolytic se fusionan para convertirse en Kymos Group"}]},{"@type":"WebSite","@id":"https:\/\/kymos.com\/es\/#website","url":"https:\/\/kymos.com\/es\/","name":"Kymos Group","description":"Kymos Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kymos.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/kymos.com\/es\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c","name":"Joan Puig de Dou","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","caption":"Joan Puig de Dou"},"description":"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.","url":"https:\/\/kymos.com\/es\/news\/author\/joan-puig-de-dou\/"}]}},"_links":{"self":[{"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/posts\/23147","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/comments?post=23147"}],"version-history":[{"count":5,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/posts\/23147\/revisions"}],"predecessor-version":[{"id":35230,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/posts\/23147\/revisions\/35230"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/media\/21660"}],"wp:attachment":[{"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/media?parent=23147"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/categories?post=23147"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/tags?post=23147"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}